Drug General Information (ID: DDILBV4ZJ2)
Drug Name			Tenecteplase		Drug Info		Caplacizumab		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Thrombolytics				Platelet Aggregation Inhibitors

Mechanism of Tenecteplase-Caplacizumab Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Tenecteplase				Caplacizumab
Mechanism		Risk of bleeding Thrombolytic agent				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Tenecteplase and Caplacizumab

Recommended Action
Management		Caution is recommended if caplacizumab must be used with other agents that affect hemostasis. Patients should be monitored for potential bleeding complications and therapy interrupted if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Cablivi (caplacizumab). Genzyme Corporation, Cambridge, MA.